Zentalis' cancer drug azenosertib resumes enrollment after FDA lifts partial clinical hold.

Zentalis Pharmaceuticals' stock rose 35% after the FDA lifted a partial clinical hold on its cancer drug, azenosertib, an orally bioavailable WEE1 inhibitor. This allows the company to resume enrollment in all ongoing studies without altering the clinical development plan. Zentalis is working with trial investigators to restart activities and remains on track to meet its data guidance for 2024, including key study results later this year.

September 16, 2024
9 Articles

Further Reading